FDMT 4D Molecular Therapeutics
- 7.840
- -0.030-0.38%
- 7.910
- +0.070+0.89%
About 4D Molecular Therapeutics Company
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
Company Profile
Company Executives
- Name
- Position
- Salary
- David Kirn, M.D.
- Director and Chief Executive Officer
- 10.29M
- Noriyuki Kasahara, M.D.,PhD
- Chief Scientific Officer
- 488.91K
- Dr. Fariborz Kamal, PhD
- President and Chief Operating Officer
- 4.54M
- Robert Young Kim, M.D.
- Chief Medical Officer
- 3.96M
- Uneek Mehra
- Chief Business Officer, Chief Financial Officer and Principal Accounting Officer
- --
- Dr. John F. Milligan, PhD
- Executive Chairman of the Board
- 581.44K
- Jacob M. Chacko, M.B.A.,M.D.
- Independent Director
- 352.62K
- Susannah Gray, M.B.A.
- Independent Director
- 352.62K
- Nancy Miller-Rich
- Independent Director
- 340.12K
- Shawn Cline Tomasello, M.B.A.
- Independent Director
- 345.12K
- Dr. Charles P. Theuer, M.D.,PhD
- Independent Director
- 352.62K
- Scott Bizily, J.D.,PhD
- Chief Legal and Corporate Secretary
- --
Analysis
Price Target
No Data
No Data